Entrada Therapeutics, Inc. Common Stock (TRDA) is a publicly traded Healthcare sector company. As of November 5, 2026, TRDA trades at $5.06 with a market cap of $183.78M and a P/E ratio of -1.59. TRDA moved -0.10% today. Year to date, TRDA is -51.85%; over the trailing twelve months it is -23.63%. Its 52-week range spans $4.10 to $16.45. Analyst consensus is strong buy with an average price target of $19.67. Rallies surfaces TRDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks TRDA insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $5.06 |
| Market Cap | $183.78M |
| P/E Ratio | -1.59 |
| EPS | $-3.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.45 |
| 52-Week Low | $4.10 |
| Volume | 14 |
| Avg Volume | 0 |
| Revenue (TTM) | $25.42M |
| Net Income | $-143.75M |
| Gross Margin | 0.00% |
5 analysts cover TRDA: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $19.67.